This February, Stockholm-based drug developer Sprint Bioscience announced that Erik Kinnman will take over as CEO of the company. The company specialises in preclinical development of small molecules within oncology. In an interview with BioStock, Kinnman talks more about his background, his view on the company and the business model.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital.https://www.biostock.se